Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on the frontline management of ALK rearranged non-small cell lung cancer with lorlatinib.
The ALK gene encodes a transmembrane tyrosine kinase receptor which is expressed physiologically during embryogenesis and its expression decreases postnatally. The rearrangements of ALK were first identified in 2007 in NSCLC, and it is observed that the 3′ region of the ALK gene gets fused with the 5′ sequence of the echinoderm microtubule-associated protein-like 4 (EML4) gene. This rearrangement results in the expression of the EML4-ALK fusion protein.
This EML4–ALK proteins are highly transforming and pathogenic. In case of NSCLC an increase in oligomerization and constitutive, kinase-activating autophosphorylation is observed involving several signaling pathways such as RAS/MAP kinase and others which leads to cell proliferation and de-differentiation.
Lorlatinib can be used in such cases as the clinical trials have shown the robust systemic and intracranial anti-tumor activity of lorlatinib in ALK rearranged advanced NSCLC. Moreover, the adverse events of the drug are also unique and manageable.
Therefore, listen to the webinar, grab the shared knowledge, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Three out of ten breast cancers detected between screenings, study finds
2.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
3.
Where Did This Very Painful Gluteal Mass Come From?
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
Rucaparib Delays Next Lines of Therapy in Ovarian Cancer
1.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
2.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
3.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
4.
Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes
5.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Evidence-Based Oncology
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation